ReviewImmunopharmacology and immunotoxicology2016
Detection of autoantibodies using chemiluminescence technologies.
Review in Immunopharmacology and immunotoxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Accuracy of IgA Anti-Transglutaminase Assessed by Chemiluminescence: A Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Calprest ELISA vs. LiaisonBiomedicines · 2026Article
- Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- [Obstetric Antiphospholipid Syndrome: Insights on the Diagnosis, Treatment, and Hot Issues].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China.Lupus science & medicine · 2023Article
- Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases.Arthritis research & therapy · 2022Article
- Fibromyalgia and Depression in Women: An 1H-NMR Metabolomic Study.Metabolites · 2021Article
- Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity.Immunity, inflammation and disease · 2021Article
- Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort.Frontiers in immunology · 2021Article
- Review
- Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China.Clinical rheumatology · 2019Article
- A Monoclonal Antibody to M-Phase Phosphoprotein 1/Kinesin-Like Protein KIF20B.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2019Article
- Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests.Immunologic research · 2018Article
- Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance.Frontiers in immunology · 2018Article
- Emerging technologies in autoantibody testing for rheumatic diseases.Arthritis research & therapy · 2017Review
- Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus.Journal of immunology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAlthough autoantibody detection methods such as indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISAs) have been available for many years and are still in use the innovation of fast, fully automated instruments using chemiluminescence technology in recent years has led to rapid adoption in autoimmune disease diagnostics. In 2009, BIO-FLASH, a fully automated, random access chemiluminescent analyzer, was introduced, proceeded by the development of the QUANTA Flash chemiluminescent immunoassays (CIA) for autoimmune diagnostics.
objectiveTo summarize the evolution of CIAs for the detection of autoantibodies and to review their performance characteristics.
methodsPubmed was screened for publications evaluating novel QUANTA Flash assays and how they compare to traditional methods for the detection of autoantibodies. In addition, comparative studies presented at scientific meetings were summarized.
resultsSeveral studies were identified that compared the novel CIAs with conventional methods for autoantibody detection. The agreements ranged from moderate to excellent depending on the assay. The studies show how the CIA technology has enhanced the analytical and clinical performance characteristics of many autoantibody assays supporting both diagnosis and follow-up testing.
conclusionCIA has started to improve the diagnostic testing of autoantibodies as an aid in the diagnosis of a broad range of autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.